{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:08:34Z","timestamp":1793214514978,"version":"4.5.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1001\/jamaneurol.2020.1162","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T19:36:05Z","timestamp":1589830565000},"page":"937","source":"Crossref","is-referenced-by-count":147,"title":["Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events"],"prefix":"10.1001","volume":"77","author":[{"given":"Amy","family":"Kunchok","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Allen J.","family":"Aksamit","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John M.","family":"Davis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun H.","family":"Kantarci","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Mark","family":"Keegan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi200026r1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1053\/j.gastro.2014.09.031","article-title":"Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn\u2019s disease after surgery: a systematic review and network meta-analysis.","volume":"148","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"issue":"8930","key":"noi200026r2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"issue":"12","key":"noi200026r3","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1097\/MIB.0000000000000533","article-title":"New insights into the mechanisms of action of anti-tumor necrosis factor-a monoclonal antibodies in inflammatory bowel disease.","volume":"21","author":"Slevin","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"noi200026r4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"noi200026r5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study.","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","year":"1999","journal-title":"Neurology"},{"issue":"12","key":"noi200026r6","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"noi200026r7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis: from the Safety Assessment of Biologic ThERapy (SABER) Study.","volume":"155","author":"Winthrop","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"noi200026r8","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents: a review of 12,731 cases (BIOGEAS Registry).","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"noi200026r9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","article-title":"Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.","volume":"48","author":"Da\u00efen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"noi200026r10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11926-015-0545-9","article-title":"Drug-induced vasculitis: new insights and a changing lineup of suspects.","volume":"17","author":"Grau","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"noi200026r11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/09546634.2015.1136385","article-title":"Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: a review.","volume":"27","author":"Zhu","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"noi200026r12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-a therapy: a French national survey.","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"17","key":"noi200026r13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1212\/WNL.0000000000006397","article-title":"Pearls & Oy-sters: Rheumatoid meningitis occurring during treatment with etanercept.","volume":"91","author":"Gherghel","year":"2018","journal-title":"Neurology"},{"key":"noi200026r14","article-title":"A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature.","volume":"2015","author":"Berrios","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"5","key":"noi200026r15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1159\/000116980","article-title":"Pachymeningeal thickening in rheumatoid arthritis.","volume":"33","author":"Micheli","year":"1993","journal-title":"Eur Neurol"},{"issue":"8297","key":"noi200026r16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(82)90629-8","article-title":"Association of ulcerative colitis with multiple sclerosis.","volume":"2","author":"Rang","year":"1982","journal-title":"Lancet"},{"issue":"11","key":"noi200026r17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1474-4422(06)70552-X","article-title":"Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study.","volume":"5","author":"Barcellos","year":"2006","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi200026r18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1053\/j.gastro.2005.06.022","article-title":"Increased risk for demyelinating diseases in patients with inflammatory bowel disease.","volume":"129","author":"Gupta","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"noi200026r19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-016-8340-8","article-title":"Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.","volume":"264","author":"Kosmidou","year":"2017","journal-title":"J Neurol"},{"issue":"6","key":"noi200026r20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.20827","article-title":"Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis.","volume":"51","author":"Singh","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"noi200026r21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi200026r22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"noi200026r23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis.","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"noi200026r24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/annrheumdis-2015-208490","article-title":"Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.","volume":"75","author":"Dreyer","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"noi200026r25","first-page":"732","article-title":"Aseptic meningitis occurring during anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis.","volume":"32","author":"Cavazzana","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"noi200026r26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/08998280.2016.11929419","article-title":"Rheumatoid meningitis associated with infliximab.","volume":"29","author":"Seago","year":"2016","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"5","key":"noi200026r27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1684\/ejd.2015.2558","article-title":"Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-a therapy in psoriatic arthritis.","volume":"25","author":"Honda","year":"2015","journal-title":"Eur J Dermatol"},{"issue":"5","key":"noi200026r28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/01.SMJ.0000155499.21189.75","article-title":"Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum?","volume":"98","author":"Hegde","year":"2005","journal-title":"South Med J"},{"issue":"2","key":"noi200026r29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000458405","article-title":"Infliximab-induced aseptic meningitis during the treatment of psoriatic arthritis.","volume":"9","author":"Matsuura-Otsuki","year":"2017","journal-title":"Case Rep Dermatol"},{"issue":"1","key":"noi200026r30","doi-asserted-by":"crossref","DOI":"10.14309\/crj.2018.48","article-title":"Infliximab-induced aseptic meningitis in a patient with Crohn\u2019s disease.","volume":"5","author":"Junga","year":"2018","journal-title":"ACG Case Rep J"},{"issue":"7","key":"noi200026r31","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/gut.2006.093294","article-title":"Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease.","volume":"55","author":"Quispel","year":"2006","journal-title":"Gut"},{"key":"noi200026r32","article-title":"Rheumatoid meningoencephalitis: a feared condition in the era of TNF blockers.","volume":"2018","author":"Figueroa Rodriguez","year":"2018","journal-title":"Case Rep Rheumatol"},{"issue":"9295","key":"noi200026r33","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/S0140-6736(01)06810-6","article-title":"Infliximab-induced aseptic meningitis.","volume":"358","author":"Marotte","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"noi200026r34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000258","article-title":"Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease.","volume":"3","author":"Zeydan","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"noi200026r35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"noi200026r36","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series.","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"noi200026r37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.amjoto.2015.09.012","article-title":"Multiple cranial neuropathies following etanercept administration.","volume":"37","author":"Hunter","year":"2016","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"noi200026r38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1471-2377-13-212","article-title":"Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis.","volume":"13","author":"Durel","year":"2013","journal-title":"BMC Neurol"},{"issue":"11","key":"noi200026r39","first-page":"2313","article-title":"Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab.","volume":"34","author":"Sturfelt","year":"2007","journal-title":"J Rheumatol"},{"issue":"2","key":"noi200026r40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00415-012-6726-9","article-title":"Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitors.","volume":"260","author":"Mao-Draayer","year":"2013","journal-title":"J Neurol"},{"issue":"3","key":"noi200026r41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection.","volume":"36","author":"Furst","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"noi200026r42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-a blockers.","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"9","key":"noi200026r43","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"noi200026r44","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fimmu.2018.00444","article-title":"Tumor necrosis factor a and regulatory T cells in oncoimmunology.","volume":"9","author":"Salomon","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"noi200026r45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/apt.2015.41.issue-1","article-title":"Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients.","volume":"41","author":"De Felice","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"noi200026r46","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease.","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"noi200026r47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2765970\/jamaneurology_kunchok_2020_oi_200026_1596744493.35135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T03:20:55Z","timestamp":1615778455000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2765970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.1162","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}